Glucagon analogues
US7994122B2 · kind B2 · utility
55Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 16, 2008 |
| Grant date | Aug 9, 2011 |
| Priority date | — |
| Expiry date | Jun 16, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P3/04
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The invention provides materials and methods for promoting weight loss or preventing weight gain in a subject. In particular, the invention provides novel glucagon analogue peptides effective in such methods and in the treatment of obesity, eating disorders, metabolic syndrome, and non-alcoholic liver steatosis. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.